“a favorable trend”

Although statistical significance was not reached for some outcomes, this analysis showed a favorable trend for the ESD technique.

Six-month survival showed a favorable trend, although not statistically significant in point analysis.

Additionally, while there was a favorable trend toward a reduction in urinary albumin-to-creatinine ratio (UACR) in the ocedurenone group, this change did not reach statistical significance within the study period [ 73 ].

In our study, post‐slaughter HSCW showed a favorable trend towards the FDL group, suggesting potential benefits from the supplementation.

5 Our findings, which indicate a favorable trend for survival outcomes, 1 support the use of pCR as a surrogate endpoint for survival outcomes in gastric cancer, particularly in the context of perioperative immunotherapy.

In contrast, NRAS mutations were linked to improved survival (HR, 0.60; 95% CI, 0.39-0.94; P = .027), whereas IDH1 (HR, 0.58; 95% CI, 0.31-1.09; P = .092) and IDH2 (HR, 0.56; 95% CI, 0.30-1.02; P = .057) mutations showed a favorable trend nearing significance.

This suggested a favorable trend for both wound healing and infection resolution.

S5 and S6, showing a favorable trend in most domains.

Clinically, patients with a prior TACE history showed a favorable trend compared with TACE-naïve patients.

Overall, SGLT2i showed a superior profile in terms of anthropometric outcomes and liver enzyme improvement, with a favorable trend across most markers, particularly in the placebo subgroup, reinforcing their potential role in metabolic dysfunction-associated conditions like MASLD/NASH.

In contrast, a favorable trend was shown in non-HDL-C, TC, and median TG levels [ 23 , 24 ].

Our ECGEA cohort of ESCC patients receiving anti–PD-1 monotherapy demonstrated that high ENTPD1 (CD39) expression was associated with improved clinical outcomes (log rank P = 1.5 × 10 − 11 ), with a Cox HR of 0.35 (95% CI 0.09–1.31), indicating a favorable trend with imprecise effect (Fig. 5i ).

60.0 %) and showed a favorable trend in persistent AF. 40 Although procedure durations and energy delivery times increased, no procedure-related deaths were reported.

Thus, a single-center study with a prospective cohort of 44 adult glioblastoma patients combined volumetric MRI-based extent-of-resection analysis with rapid PCR-based detection of TERT promoter mutation at the surgical margin and found that achieving an undetectable molecular margin was associated with significantly prolonged PFS and a favorable trend for OS [ 102 ].

31 Although the updated OS data presented at the 2025 ASCO annual meeting showed a favorable trend, statistical significance was not reached. 32 Moreover, another retrospective study reported that adjuvant nivolumab following neoadjuvant DCF chemotherapy could further improve both disease-free survival and OS in patients with locally advanced ESCC, with particularly pronounced benefits observed in those with ypStage III disease. 33 These studies suggest that patients who fail to achieve a complete pathological response may still benefit from intensified adjuvant therapy.

Additionally, with the passage of time, the AQ and CTQ traits showed a favorable trend of change.

Although the predefined clinical significance criteria were not fully met, the program demonstrated a favorable trend toward improved efficiency and patient-centered care.

MFC-MRD–free survival showed a favorable trend in the maintenance group, although this did not reach statistical significance (2-year MFC-MRD–free survival: 85.5% [95% CI, 74.4–98.3] vs. 68.7% [95% CI, 57.3–82.4], p = 0.051).

Although the proportion of patients from the BRV group who entered into the open phase of the individual trials did not generally show a favorable trend compared to the placebo group, a meta-analysis of trials of adjunctive AEDs in adults with drug-resistant focal epilepsy found the responder rates to placebo virtually double between 1989 and 2009. 100 This may partially explain the unnoticeable difference between BRV and placebo groups.

Pre-transplant TKI use showed a favorable trend on PRS after stratifying by the disease status ( Figure 1D ).

TAPB showed a favorable trend toward reduced postoperative nausea and vomiting, though with high heterogeneity.

Other interventions, such as TEII (SMD = 0.48) and TWDT (SMD = 0.37), also showed trends of being showed a favorable trend to the control group, but with wider confidence intervals and greater uncertainty.

In the subgroup analysis by country, both Chinese and non-Chinese studies showed a favorable trend for higher PNI, and no significant subgroup difference was detected (P=0.59).

The results showed a favorable trend for depressive symptom reduction, but the overall evidence remained uncertain.

The camrelizumab group (HR: 0.218, 95% CI: 0.026–1.844, p = 0.162) showed a favorable trend, but the result was not statistically significant, likely due to small sample size and high censoring rate.